Eclipse Life Sciences Reports Positive Phase 2 Results for EC-104 in Anti-VEGF-Resistant Diabetic Macular Edema

AI-generated NewsSnap summary based on source reporting.
Published: 2026-10-15
Category: health
Source: Eye Care Network - Modern Retina - Ophthalmology Times

Eclipse Life Sciences announced positive topline results from its Phase 2 BETTIS-1 trial, demonstrating that its EC-104 fluocinolone acetonide extended-release implant showed superior and clinically meaningful improvements in visual acuity and central subfield thickness compared to Ozurdex in patients with diabetic macular edema resistant to anti-VEGF therapy.

Want more?

Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.

Open NewsSnap.ai